Back to top
more

Insmed (INSM)

(Delayed Data from NSDQ)

$56.85 USD

56.85
2,186,309

-0.32 (-0.56%)

Updated Jun 7, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 248)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for INSM

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Insmed, Inc. [INSM]

Reports for Purchase

Showing records 81 - 100 ( 113 total )

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 81

02/11/2014

Company Report

Pages: 8

Downgrading to UNDERPERFORM from OUTPERFORM - Adjusting Model to Reflect the Timing Associated with a U.S. Phase III for NTM Approval

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 82

02/02/2014

Industry Report

Pages: 6

The Week Ahead in Life Sciences - Upcoming Events for the Week of Feb. 3

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 83

01/17/2014

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of Jan. 20

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 84

12/30/2013

Daily Note

Pages: 5

LIFE SCIENCES AND HEALTH CARE

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 85

12/08/2013

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec. 9

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 86

10/15/2013

Daily Note

Pages: 4

NTM Phase II Fully Enrolled With Baseline Culture Results In-Line For 80% Statistical Power - Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 87

08/08/2013

Company Report

Pages: 6

Q2:13 Update

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 88

07/01/2013

Company Report

Pages: 9

Arikace Non-Inferior -- Phase IIb NTM data Q1:14; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 89

06/30/2013

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of July 1

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 90

05/22/2013

Company Report

Pages: 12

Increasing Price Target to $18 - Positive Data Likely Additional Upside in NTM YE:13 - Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 91

04/07/2013

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of April 8

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 92

03/19/2013

Company Report

Pages: 6

Q4:12 Update - Clean Dog Tox Data Removes Overhang, Focus on Commercial Strategy Emerges -Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 93

03/15/2013

Industry Report

Pages: 5

LIFE SCIENCES-The Week Ahead in Life Sciences - Upcoming Events for the Week of March 18

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 94

03/03/2013

Daily Note

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of March 4

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 95

11/07/2012

Company Report

Pages: 6

Q3:12 Update - 2013 Transformational with ARIKACE in CF and NTM - Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 96

08/15/2012

Industry Report

Pages: 12

Life Sciences MAC Best Ideas Conference - New York City

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 97

08/07/2012

Company Report

Pages: 6

Q2:12 Update - ARIKACE for NTM Opportunity Remains Overlooked and Undervalued - Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 98

05/30/2012

Daily Note

Pages: 4

Insmed Confirms Development Plans for ARIKACE - CF and NTM Trials Underway - Dog Study Data YE:12 - Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 99

05/24/2012

Company Report

Pages: 9

Increasing Price Target to $11- Near-Billion Dollar Opportunity in NTM Lung Diseases Underappreciated

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 100

05/08/2012

Company Report

Pages: 6

Q1:12 Results - EU Phase III Progressing Well as CF Program Masks NTM Opportunity - REITERATE

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party